CSL stock: CSL annual meeting is set for October 27, 2026

Published on 10/19/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

In fiscal year 2026, revenue fell 1.00 percent to USD 15.8 billion. CSL stock costs EUR 119.20 on October 19, 2026 at 4:07 p.m. CEST.

Dates and operating scale

CSL's annual meeting is scheduled for October 27, 2026.
Fiscal year 2026 revenue fell 1.00 percent to USD 15.8 billion.
CSL stock costs EUR 119.20 at 4:07 p.m. CEST at Lang & Schwarz on October 19, 2026.
CSL's market capitalization was AUD 93.1 billion on October 19, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL Limited (AU000000CSL8) has its annual meeting scheduled for October 27, 2026, giving investors the next fixed date for the Australian biopharmaceutical group. Veye lists the meeting date and the planned release of first-half fiscal 2027 results on February 10, 2027. CSL stock was trading at EUR 119.20 at Lang & Schwarz on October 19, 2026 at 4:07 p.m. CEST.

Fiscal year 2026 reset

The latest reported operating picture is mixed. In fiscal year 2026, revenue fell 1.00 percent to USD 15.8 billion, while underlying net profit after tax declined 2.00 percent to USD 3.1 billion, according to Veye. The statutory result was a USD 2.6 billion net loss, alongside USD 7.1 billion in pretax impairments and USD 799.0 million in restructuring costs.

That distinction matters for the calendar ahead. CSL's fiscal year 2027 outlook calls for underlying net profit after tax growth of 5.00 percent, while group revenue is expected to remain broadly flat, with the guidance reported by Veye. The October meeting therefore arrives before the next half-year results and provides a near-term corporate date rather than a new earnings release.

Price position and trading scale

The Lang & Schwarz euro quote stood at EUR 119.20 at 4:07 p.m. CEST on October 19, 2026. The latest primary-market quote for CSL Limited was AUD 194.05 at 4:10 p.m. AEDT on October 19, 2026, with 941,254 shares traded against an average volume of 1,272,237 shares.

The primary-market 52-week range was AUD 90.00 to AUD 221.76 on October 19, 2026. The market capitalization was AUD 93.1 billion, while the reported trailing price-to-earnings ratio was minus 25.60 and the dividend yield was 0.02 percent.

Dates and operating risks

The October 27 annual meeting is the next dated corporate event, followed by the February 10, 2027 first-half results. CSL's operating plan also includes USD 400.0 million of targeted savings in fiscal year 2027, rising to as much as USD 550.0 million in fiscal year 2028, according to Veye.

The main counterweight is execution. The same fiscal year 2027 outlook expects CSL Vifor revenue to decline 25.00 percent, while CSL Behring is expected to deliver mid-single-digit revenue growth and Seqirus low-single-digit growth.

Market context for CSL

CSL Limited is listed on the Australian Securities Exchange under ticker CSL and operates in biotechnology, with CSL Behring and CSL Seqirus as its principal operating segments. Its business spans plasma-derived therapies, vaccines and other biopharmaceutical products.

CSL stock at Lang & Schwarz

CSL stock was trading at EUR 119.20 at Lang & Schwarz on October 19, 2026 at 4:07 p.m. CEST. The primary-market figures place the company at AUD 93.1 billion in market capitalization, with a 52-week range of AUD 90.00 to AUD 221.76.

The further course of trading is shown by the continuously updated real-time quote of CSL stock.